These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 5922724)

  • 21. [Long-term clinical study and serial determination of urinary catecholamines using the new antihypertensive agent ST-155].
    Villalpando J; Skromme D; Chávez B; Serrano P
    Arch Inst Cardiol Mex; 1968; 38(6):841-50. PubMed ID: 5711376
    [No Abstract]   [Full Text] [Related]  

  • 22. [A new antihypertensive imidazoline derivative (St 600, Fluoronidine): I. Haemodynamic investigations at rest and during exercise (author's transl)].
    Djawan S; Mlezoch J; Niederberger M; Penner E; Grabner G
    Wien Klin Wochenschr; 1976 Mar; 88(6):199-206. PubMed ID: 973381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blind trial with 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST 155) in essential hypertension. Effects on arterial blood pressures at rest and during exercise and on physical work capacity.
    Koch G
    Arzneimittelforschung; 1970 Dec; 20(12):1857-9. PubMed ID: 5537080
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension].
    Zaslavskaia RM; Komarov FI; Shakirova AN; Teĭblium MM; Akhmetov KZh
    Klin Med (Mosk); 2000; 78(4):41-4. PubMed ID: 10833890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [First experiences with BS 100-141, a new antihypertensive substance].
    Esch I
    Int J Clin Pharmacol Biopharm; 1976 Sep; 14(2):109-12. PubMed ID: 793999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New antihypertensive agent of the imidazoline series: 5-fluoro-methyl-imidazolidinylidene-benzamine-monohydrochloride (flutonidin)].
    Brunner H; Djawan S; Dorda W; Penner E; Grabner G
    Arzneimittelforschung; 1977; 27(8):1599-604. PubMed ID: 334188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Long-term experiences with moxonidine, a new antihypertensive agent].
    Schwarz W; Kandziora J
    Fortschr Med; 1990 Nov; 108(32):616-20. PubMed ID: 2262193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of severe hypertension with Catapresan. A comparative study of the effects of Catapresan and methyldopa on ambulant hypertensive patients].
    Becker-Christensen F; Bang HO; Ditzel J
    Ugeskr Laeger; 1970 Dec; 132(49):2331-6. PubMed ID: 5488234
    [No Abstract]   [Full Text] [Related]  

  • 30. [Blood pressure-lowering treatment for the reduction of the cardiovascular complications of hypertension].
    Birkenhäger WH
    Ned Tijdschr Geneeskd; 1985 Dec; 129(49):2341-3. PubMed ID: 4088334
    [No Abstract]   [Full Text] [Related]  

  • 31. [High blood pressure discovered by a causal measurement. Problems concerning diagnosis of hypertension and selection of antihypertensive treatment].
    Hansen OP; Hansen M; Lindholm J
    Ugeskr Laeger; 1978 Nov; 140(47):2923-6. PubMed ID: 715906
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of antihypertensive drugs in the therapy of patients on regular dialysis treatment.
    Sulková S; Válek A
    Kidney Int Suppl; 1988 Sep; 25():S198-200. PubMed ID: 3184612
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical experiences with 2-(2,6-dichlorphenylamino)-2-imidazolinhydrochloride in renal hypertension].
    Kotzaurek R; Schmidt P; Widhalm F
    Wien Klin Wochenschr; 1970 Nov; 82(45):805-9. PubMed ID: 5479019
    [No Abstract]   [Full Text] [Related]  

  • 34. Hypertension and the kidney: new avenues for an improved management of hypertension in renal diseases: introduction.
    Burnier M
    Semin Nephrol; 2007 Sep; 27(5):509-10. PubMed ID: 17868786
    [No Abstract]   [Full Text] [Related]  

  • 35. [Controlled studies on the therapeutic efficacy of a new antihypertensive agent: Aldatense].
    Barbara L; Melchionda N
    Minerva Cardioangiol; 1972 Sep; 20(9):516-25. PubMed ID: 5071472
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical experience with a new hypotensive drug: 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (ST-155)].
    Langer-Costanzi M
    Clin Ter; 1970 Dec; 55(5):419-31. PubMed ID: 5516107
    [No Abstract]   [Full Text] [Related]  

  • 37. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new preparation for the treatment of hypertension: Envarese (guanoxan plus polythiazide).
    Ozen MA; Kadioglu A; Saribeyler G
    Curr Ther Res Clin Exp; 1966 Aug; 8(8):384-90. PubMed ID: 4958154
    [No Abstract]   [Full Text] [Related]  

  • 39. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials.
    Hsu CY
    J Hum Hypertens; 2001 Feb; 15(2):99-106. PubMed ID: 11317188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical experiences with a new antihypertensive agent].
    Lieb W; Ridders K
    Arzneimittelforschung; 1966 Dec; 16(12):1610-5. PubMed ID: 6014793
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.